Oncodesign, Covalab, CheMatech and ABX-CRO launch DRIVE™-MRT
A premium complete, integrated service offer for radiopharmaceuticals drug discovery and generation
Financial
Financial
16/09/2021
Oncodesign announces its results for the first half of 2021
Read all the financial information of Oncodesign and its Business Units Service, Biotech and Artificial Intelligence.
Financial
21/07/2021
Oncodesign announces a sharp increase in turnover in the first half of 2021
Group turnover up by 33% at €15.8M. Despite the global health crisis, which continues to limit international travel...
Corporate
Financial
05/07/2021
Oncodesign announces the appointment of Aline Aubertin as an independent director of the Board of Directors
Oncodesign strenghens its Board by appointing Aline Aubertin as new independent director.
Service
Financial
Oncodesign launches its new DRIVE-MRT™ service offer in partnership with Covalab, CheMatech and ABX-CRO
[Press Release] Explore our brand new service offer DRIVE-MRT. it allows the rationalization, design and optimization of targeted radiopharmaceutical products that are effective against certain metastatic cancers.
Biotech
Financial
24/06/2021
Oncodesign provides an update on its progress on RIPK2
[Press Release] Find the update of the RIPK2 program and the start of new programs associated with Nanocyclix.
Financial
18/06/2021
Oncodesign maintains its revenue and operating income at €38 million in 2020…
[Press Release] Oncodesign maintains its revenue and operating income at €38 million in 2020 and is anticipating an operating profit for the 2nd straight year, within the context of the global public health crisis
Financial